Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.28 CHF -0.55% Market Closed
Market Cap: 145.3m CHF

Intrinsic Value

NWRN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NWRN stock under the Base Case scenario is 10.14 CHF. Compared to the current market price of 7.28 CHF, Newron Pharmaceuticals SpA is Undervalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NWRN Intrinsic Value
10.14 CHF
Undervaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Newron Pharmaceuticals SpA

Valuation History Unavailable

Historical valuation for NWRN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Newron Pharmaceuticals SpA
SIX:NWRN
IT
Pharmaceuticals
Market Cap
145.3m CHF
IPO
Dec 12, 2006
IT
Pharmaceuticals
Market Cap
145.3m CHF
IPO
Dec 12, 2006
Price
CHffalse
EPS
€false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NWRN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Newron Pharmaceuticals SpA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Newron Pharmaceuticals SpA

Current Assets 61.1m
Cash & Short-Term Investments 9.8m
Receivables 47.1m
Other Current Assets 4.2m
Non-Current Assets 2.8m
PP&E 834k
Other Non-Current Assets 2m
Efficiency

Free Cash Flow Analysis
Newron Pharmaceuticals SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Newron Pharmaceuticals SpA

Revenue
51.4m EUR
Cost of Revenue
-892k EUR
Gross Profit
50.5m EUR
Operating Expenses
-24.3m EUR
Operating Income
26.2m EUR
Other Expenses
-10.3m EUR
Net Income
15.8m EUR
Fundamental Scores

NWRN Profitability Score
Profitability Due Diligence

Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional ROIC
Exceptional 1-Year Revenue Growth
37/100
Profitability
Score

Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

NWRN Solvency Score
Solvency Due Diligence

Newron Pharmaceuticals SpA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Short-Term Solvency
Long-Term Solvency
57/100
Solvency
Score

Newron Pharmaceuticals SpA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 16.76 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

Lowest
Price Target
11.62 CHF
60% Upside
Average
Price Target
16.76 CHF
130% Upside
Highest
Price Target
26.25 CHF
261% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Newron Pharmaceuticals SpA
does not pay dividends
Shareholder Yield

Current shareholder yield for NWRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

NWRN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one NWRN stock?

The intrinsic value of one NWRN stock under the Base Case scenario is 10.14 CHF.

Is NWRN stock undervalued or overvalued?

Compared to the current market price of 7.28 CHF, Newron Pharmaceuticals SpA is Undervalued by 28%.

Back to Top